Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas

Cytogenetic and Genome Research

Volumn 118, Issue 2-4, 2007, Pages 157-165

  Medendorp, K ^a   Van Groningen, J J M ^a   Schepens, M ^a   Vreede, L ^a   Thijssen, J ^a   Schoenmakers, E F P M ^a   Van Den Hurk, W H ^a   Geurts Van Kessel, A ^a   Kuiper, R P ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; LEUCINE ZIPPER PROTEIN; MIT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG;

CANCER GROWTH; CELL MATURATION; CHROMOSOME TRANSLOCATION; GENE CONTROL; GENE DISRUPTION; GENE FUNCTION; GENE FUSION; GENE TRANSLOCATION; HUMAN; KIDNEY CARCINOMA; KIDNEY PROXIMAL TUBULE; NEPHRON; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; TUMOR LOCALIZATION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; GENE FUSION; HUMANS; KIDNEY NEOPLASMS; NEOPLASM PROTEINS; TRANSLOCATION, GENETIC;

EID: 36249026571     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108296     Document Type: Review

References (118)

1. Argani P: The evolving story of renal translocation carcinomas. Am J Clin Pathol 126:332-334 (2006).
2. Argani P, Ladanyi M: Distinctive neoplasms characterised by specific chromosomal translocations comprise a significant proportion of paediatric renal cell carcinomas. Pathology 35:492-498 (2003).
3. Argani P, Ladanyi M: Translocation carcinomas of the kidney. Clin Lab Med 25:363-378 (2005).
4. Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, et al: Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159:179-192 (2001a).
5. Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, et al: A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6; 11)(p21.1; q12) chromosome translocation. Am J Pathol 158:2089-2096 (2001b).
6. Argani P, Lui MY, Couturier J, Bouvier R, Fournet JC, et al: A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17) (p11.2;q23). Oncogene 22:5374-5378 (2003).
7. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, et al: Renal carcinomas with the t(6; 11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 29:230-240 (2005).
8. Argani P, Lae M, Ballard ET, Amin M, Manivel C, et al: Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 24:1529-1534 (2006).
9. Artandi SE, Merrell K, Avitahl N, Wong KK, Calame K: TFE3 contains two activation domains, one acidic and the other proline-rich, that synergistically activate transcription. Nucleic Acids Res 23:3865-3871 (1995).
10. Balaban G, Herlyn M, Guerry D, Bartolo R, Koprowski H, et al: Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 11:429-439 (1984).
11. Beckmann H, Su LK, Kadesch T: TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev 4:167-179 (1990).
12. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61:49-59 (1990).
13. Bodmer D, van den Hurk WH, van Groningen JJM, Eleveld MJ, Martens GJ, et al: Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489-2498 (2002).
14. Bonham K, Ritchie SA, Dehm SM, Snyder K, Boyd FM: An alternative, human SRC promoter and its regulation by hepatic nuclear factor-1alpha. J Biol Chem 275:37604-37611 (2000).
15. Busca R, Berra E, Gaggioli C, Khaled M, Bille K, et al: Hypoxia-inducible factor 1(alpha) is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol 170:49-59 (2005).
16. Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, et al: Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics 58:181-187 (1999).
17. Carcao MD, Taylor GP, Greenberg ML, Bernstein ML, Champagne M, et al: Renal-cell carcinoma in children: a different disorder from its adult counterpart? Med Pediatr Oncol 31:153-158 (1998).
18. Clark J, Lu YJ, Sidhar SK, Parker C, Gill S, et al: Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 15:2233-2239 (1997).
19. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 353:2477-2490 (2005).
20. Dal Cin P, Van Gool S, Brock P, Proesmans W, Casteels-Van Daele M, et al: Renal cell carcinoma in a child. Cancer Genet Cytogenet 57:137-138 (1991).
21. Dal Cin P, Stas M, Sciot R, de Wever I, Van Damme B, et al: Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet 101:58-61 (1998).
22. Davis IJ, Hsi BL, Arroyo JD, Vargas SO, Yeh YA, et al: Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6; 11)(p21;q13) chromosome translocation. Proc Natl Acad Sci USA 100:6051-6056 (2003).
23. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, et al: Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 9:473-484 (2006).
24. de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW: Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet 21:165-169 (1986).
25. Desangles F, Camparo P, Fouet C, Houlgatte A, Arborio M: Translocation (X;1) associated with a nonpapillary carcinoma in a young woman: a new definition for an Xp11.2 RCC subtype. Cancer Genet Cytogenet 113:141-144 (1999).
26. Dijkhuizen T, van den Berg E, Wilbrink M, Weterman M, Geurts van Kessel A, et al: Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Genes Chromosomes Cancer 14:43-50 (1995).
27. Dijkhuizen T, van den Berg E, Storkel S, Geurts van Kessel A, Janssen B, et al: Two cases of renal cell carcinoma, clear cell type, revealling a t(6; 11)(p21;q13). Cancer Genet Cytogenet 91:141 (1996).
28. Dijkhuizen T, van den Berg E, Storkel S, Terpe HI, Burger H, et al: Distinct features for chromophilic renal cell cancer with Xp11.2 breakpoints. Cancer Genet Cytogenet 104:74-76 (1998).
29. Dong B, Horowitz DS, Kobayashi R, Krainer AR: Purification and cDNA cloning of HeLa cell p54nrb, a nuclear protein with two RNA recognition motifs and extensive homology to human splicing factor PSF and Drosophila NONA/BJ6. Nucleic Acids Res 21:4085-4092 (1993). Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, et al: The candidate tumor suppressor gene, RASSF1A , from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 98:7504-7509 (2001).
30. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, et al: MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 163:333-343 (2003).
31. Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, et al: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6:565-576 (2004).
32. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: Tumors of the kidney, in World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, pp 37-38 (IARC Press, Lyon 2004).
33. Fisher DE, Carr CS, Parent LA, Sharp PA: TFEB has DNA-binding and oligomerization properties of a unique helix-loop-helix/leucine-zipper family. Genes Dev 5:2342-2352 (1991).
34. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-122 (2005).
35. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90 (1994).
36. Gozani O, Patton JG, Reed R: A novel set of spliceosome-associated proteins and the essential splicing factor PSF bind stably to pre-mRNA prior to catalytic step II of the splicing reaction. EMBO J 13:3356-3367 (1994).
37. Hallsson JH, Favor J, Hodgkinson CA, Glaser T, Lamoreux ML, et al: Genomic, transcriptional and mutational analysis of the mouse microphthalmia locus. Genetics 155:291-300 (2000).
38. Heimann P, El Housni H, Ogur G, Weterman MA, Petty EM, et al: Fusion of a novel gene, RCC17 , to the TFE3 gene in t(X;17)(p11.2;q25.3)- bearing papillary renal cell carcinomas. Cancer Res 61:4130-4135 (2001).
39. Hemesath TJ, Steingrimsson E, McGill G, Hansen MJ, Vaught J, et al: Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev 8:2770-2780 (1994).
40. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704 (1994).
41. Hernandez-Marti MJ, Orellana-Alonso C, Badia-Garrabou L, Verdeguer MA, Paradis-Alos A: Renal adenocarcinoma in an 8-year-old child, with a t(X;17)(p11.2;q25). Cancer Genet Cytogenet 83:82-83 (1995).
42. Hua X, Liu X, Ansari DO, Lodish HF: Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev 12:3084-3095 (1998).
43. Huan C, Kelly ML, Steele R, Shapira I, Gottesman SR, et al: Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nat Immunol 7:1082-1091 (2006).
44. Jhang JS, Narayan G, Murty VV, Mansukhani MM: Renal oncocytomas with 11q13 rearrangements: cytogenetic, molecular, and immunohistochemical analysis of cyclin D1. Cancer Genet Cytogenet 149:114-119 (2004).
45. Kamat A, Hinshelwood MM, Murry BA, Mendelson CR: Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 13:122-128 (2002).
46. Kardas I, Denis A, Babinska M, Gronwald J, Podolski J, et al: Translocation (X;1)(p11.2;q21) in a papillary renal cell carcinoma in a 14-yea-rold girl. Cancer Genet Cytogenet 101:159-161 (1998).
47. Kido S, Miyamoto K, Mizobuchi H, Taketani Y, Ohkido I, et al: Identification of regulatory sequences and binding proteins in the type II sodium/phosphate cotransporter NPT2 gene responsive to dietary phosphate. J Biol Chem 274:28256-28263 (1999).
48. Kirchhausen T: Clathrin. Annu Rev Biochem 69:699-727 (2000).
49. Kovacs G, Brusa P: Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. Hum Genet 80:99-101 (1988).
50. Kovacs G, Szucs S, de Riese W, Baumgartel H: Specific chromosome aberration in human renal cell carcinoma. Int J Cancer 40:171-178 (1987).
51. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, et al: The Heidelberg classification of renal cell tumours. J Pathol 183:131-133 (1997).
52. Kuiper RP, Schepens M, Thijssen J, van Asseldonk M, van den Berg E, et al: Upregulation of the transcription factor TFEB in t(6; 11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet 12:1661-1669 (2003).
53. Kuiper RP, Schepens M, Thijssen J, Schoenmakers EFPM, Geurts van Kessel A: Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains. Nucleic Acids Res 32:2315-2322 (2004).
54. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, et al: The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL , a novel gene at 17q25. Oncogene 20:48-57 (2001).
55. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al: Initial sequencing and analysis of the human genome. Nature 409:860-921 (2001).
56. Landry JR, Mager DL: Widely spaced alternative promoters, conserved between human and rodent, control expression of the Opitz syndrome gene MID1 . Genomics 80:499-508 (2002).
57. Landry JR, Mager DL, Wilhelm BT: Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 19:640-648 (2003).
58. Langezaal SM, Graadt van Roggen JF, Cleton-Jansen AM, Baelde JJ, Hogendoorn PC: Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts). Br J Cancer 84:535-538 (2001).
59. Larsen LK, Amri EZ, Mandrup S, Pacot C, Kristiansen K: Genomic organization of the mouse peroxisome proliferator-activated receptor beta/delta gene: alternative promoter usage and splicing yield transcripts exhibiting differential translational efficiency. Biochem J 366:767-775 (2002).
60. Li R, Murray AW: Feedback control of mitosis in budding yeast. Cell 66:519-531 (1991).
61. Mansky KC, Sulzbacher S, Purdom G, Nelsen L, Hume DA, et al: The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter. J Leukoc Biol 71:304-310 (2002).
62. Mathur M, Samuels HH: Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas. Oncogene 26:277-283 (2007).
63. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275 (1999).
64. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, et al: Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109:707-718 (2002).
65. Medstrand P, Landry JR, Mager DL: Long terminal repeats are used as alternative promoters for the endothelin B receptor and apolipoprotein C-I genes in humans. J Biol Chem 276:1896-1903 (2001).
66. Meloni AM, Dobbs RM, Pontes JE, Sandberg AA: Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet 65:1-6 (1993).
67. Merrell K, Wells S, Henderson A, Gorman J, Alt F, et al: The absence of the transcription activator TFE3 impairs activation of B cells in vivo. Mol Cell Biol 17:3335-3344 (1997).
68. Modrek B, Resch A, Grasso C, Lee C: Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 29:2850-2859 (2001).
69. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, et al: Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61:7277-7281 (2001).
70. Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ, et al: Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA 98:5798-5803 (2001).
71. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875 (1996).
72. Nijman SM, Hijmans EM, El Messaoudi S, van Dongen MM, Sardet C, et al: A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. J Biol Chem 281:21582-21587 (2006).
73. Ohjimi Y, Iwasaki H, Ishiguro M, Hara H, Ohgami A, et al: Deletion (X)(p11): another case of renal adenocarcinoma with involvement of Xp11. Cancer Genet Cytogenet 70:77-78 (1993).
74. Onder AM, Teomete U, Argani P, Toledano S, Zilleruelo G, et al: PRCC-TFE3 Renal cell carcinoma in a boy with a history of contralateral mesoblastic nephroma. Pediatr Nephrol 21:1471-1475 (2006).
75. Patton JG, Porro EB, Galceran J, Tempst P, Nadal-Ginard B: Cloning and characterization of PSF, a novel pre-mRNA splicing factor. Genes Dev 7:393-406 (1993).
76. Perot C, Bougaran J, Boccon-Gibod L, Storkel S, Leverger G, et al: Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females. Cancer Genet Cytogenet 110:54-56 (1999).
77. Perot C, Boccon-Gibod L, Bouvier R, Doz F, Fournet JC, et al: Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet 143:93-99 (2003).
78. Phelps DE, Hsiao KM, Li Y, Hu N, Franklin DS, et al: Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol Cell Biol 18:2334-2343 (1998).
79. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, et al: An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304-306 (2000). Pulford K, Morris SW, Turturro F: Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330-358 (2004).
80. Ramp U, Caliskan E, Ebert T, Karagiannidis C, Willers R, et al: FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol 196:430-436 (2002).
81. Ramphal R, Pappo A, Zielenska M, Grant R, Ngan BY: Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the MiT transcription factor family. Am J Clin Pathol 126:349-364 (2006).
82. Rehli M, Lichanska A, Cassady AI, Ostrowski MC, Hume DA: TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. J Immunol 162:1559-1565 (1999).
83. Roman C, Cohn L, Calame K: A dominant negative form of transcription activator mTFE3 created by differential splicing. Science 254:94-97 (1991).
84. Royle SJ, Bright NA, Lagnado L: Clathrin is required for the function of the mitotic spindle. Nature 434:1152-1157 (2005).
85. Saleh A, Makrigiannis AP, Hodge DL, Anderson SK: Identification of a novel Ly49 promoter that is active in bone marrow and fetal thymus. J Immunol 168:5163-5169 (2002).
86. Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, et al: The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 62:2098-2103 (2002).
87. Shibahara S, Takeda K, Yasumoto K, Udono T, Watanabe K, et al: Microphthalmia-associated transcription factor (MITF): multiplicity in structure, function, and regulation. J Investig Dermatol Symp Proc 6:99-104 (2001).
88. Shipley JM, Birdsall S, Clark J, Crew J, Gill S, et al: Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. Cytogenet Cell Genet 71:280-284 (1995).
89. Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, et al: The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet 5:1333-1338 (1996).
90. Smith CJ, Pearse BM: Clathrin: anatomy of a coat protein. Trends Cell Biol 9:335-338 (1999).
91. Steingrimsson E, Moore KJ, Lamoreux ML, Ferre-D'Amare AR, Burley SK, et al: Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences. Nat Genet 8:256-263 (1994).
92. Steingrimsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG: The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. Development 125:4607-4616 (1998).
93. Steingrimsson E, Tessarollo L, Pathak B, Hou L, Arnheiter H, et al: Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. Proc Natl Acad Sci USA 99:4477-4482 (2002).
94. Steingrimsson E, Copeland NG, Jenkins NA: Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet 38:365-411 (2004).
95. Tomlinson GE, Nisen PD, Timmons CF, Schneider NR: Cytogenetics of a renal cell carcinoma in a 17-month-old child. Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet 57:11-17 (1991).
96. Tonk V, Wilson KS, Timmons CF, Schneider NR, Tomlinson GE: Renal cell carcinoma with translocation (X;1). Further evidence for a cytogenetically defined subtype. Cancer Genet Cytogenet 81:72-75 (1995).
97. Trinklein ND, Aldred SJ, Saldanha AJ, Myers RM: Identification and functional analysis of human transcriptional promoters. Genome Res 13:308-312 (2003).
98. Udono T, Yasumoto K, Takeda K, Amae S, Watanabe K, et al: Structural organization of the human microphthalmia-associated transcription factor gene containing four alternative promoters. Biochim Biophys Acta 1491:205-219 (2000).
99. van Asseldonk M, Schepens M, de Bruijn DR, Janssen B, Merkx G, et al: Construction of a 350-kb sequence-ready 11q13 cosmid contig encompassing the markers D11S4933 and D11S546: mapping of 11 genes and 3 tumor-associated translocation breakpoints. Genomics 66:35-42 (2000).
100. van den Hurk WH, Martens GJ, Geurts van Kessel A, van Groningen JJM: Isolation and characterization of the Xenopus laevis orthologs of the human papillary renal cell carcinoma-associated genes PRCC and MAD2L2 (MAD2B) . Cytogenet Genome Res 106:68-73 (2004).
101. Verastegui C, Bertolotto C, Bille K, Abbe P, Ortonne JP, et al: TFE3, a transcription factor homologous to microphthalmia, is a potential transcriptional activator of tyrosinase and TyrpI genes. Mol Endocrinol 14:449-456 (2000).
102. Wang Y, Newton DC, Robb GB, Kau CL, Miller TL, et al: RNA diversity has profound effects on the translation of neuronal nitric oxide synthase. Proc Natl Acad Sci USA 96:12150-12155 (1999).
103. Weterman MA, Wilbrink M, Geurts van Kessel A: Fusion of the transcription factor TFE3 gene to a novel gene, PRCC , in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. Proc Natl Acad Sci USA 93:15294-15298 (1996a).
104. Weterman MA, Wilbrink M, Janssen I, Janssen HA, van den Berg E et al: Molecular cloning of the papillary renal cell carcinoma-associated translocation (X;1)(p11;q21) breakpoint. Cytogenet Cell Genet 75:2-6 (1996b).
105. Weterman MJ, van Groningen JJM, Jansen A, Geurts van Kessel A: Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. Oncogene 19:69-74 (2000).
106. Weterman MA, van Groningen JJM, den Hartog A, Geurts van Kessel A: Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes. Oncogene 20:1414-1424 (2001a).
107. Weterman MA, van Groningen JJM, Tertoolen L, Geurts van Kessel A: Impairment of MAD2BPRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas. Proc Natl Acad Sci USA 98:13808-13813 (2001b).
108. Widlund HR, Horstmann MA, Price ER, Cui J, Lessnick SL, et al: Beta-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor. J Cell Biol 158:1079-1087 (2002).
109. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, et al: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2:305-316 (1998).
110. Yang YS, Hanke JH, Carayannopoulos L, Craft CM, Capra JD, et al: NonO, a non-POU-domain-containing, octamer-binding protein, is the mammalian homolog of Drosophila nonAdiss. Mol Cell Biol 13:5593-5603 (1993).
111. Ybe JA, Greene B, Liu SH, Pley U, Parham P, et al: Clathrin self-assembly is regulated by three light-chain residues controlling the formation of critical salt bridges. EMBO J 17:1297-1303 (1998).
112. Ybe JA, Brodsky FM, Hofmann K, Lin K, Liu SH, et al: Clathrin self-assembly is mediated by a tandemly repeated superhelix. Nature 399:371-375 (1999).
113. Yenamandra A, Zhou X, Trinchitella L, Susin M, Sastry S, et al: Renal cell carcinoma with X;1 translocation in a child with Klinefelter syndrome. Am J Med Genet 77:281-284 (1998).
114. Yoshida MA, Ochi-Takeuchi H, Gibas Z, Sandberg AA: Updating of chromosome changes in renal cell carcinoma. Proc AACR 28:31 (1985).
115. Zanocco-Marani T, Vignudelli T, Gemelli C, Pirondi S, Testa A, et al: Tfe3 expression is closely associated to macrophage terminal differentiation of human hematopoietic myeloid precursors. Exp Cell Res 312:4079-4089 (2006).
116. Zattara-Cannoni H, Daniel L, Roll P, Coulange C, Vagner-Capodano A: Molecular cytogenetics of t(X;1)(p11.2;q21) with complex rearrangements in a renal cell carcinoma. Cancer Genet Cytogenet 123:61-64 (2000).
117. Zhao WP, Gnarra JR, Liu S, Knutsen T, Linehan WM, et al: Renal cell carcinoma. Cytogenetic analysis of tumors and cell lines. Cancer Genet Cytogenet 82:128-139 (1995).
118. Zucman J, Delattre O, Desmaze C, Epstein AL, Stenman G, et al: EWS and ATF-1 gene fusion induced by t(12; 22) translocation in malignant melanoma of soft parts. Nat Genet 4:341-345 (1993).